Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30850494)

  • 1. Combining
    Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
    J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
    Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
    J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
    Woff E; Salvatore L; Marmorino F; Genovesi D; Critchi G; Guiot T; Ameye L; Sclafani F; Hendlisz A; Flamen P
    J Nucl Med; 2022 Apr; 63(4):549-555. PubMed ID: 34326124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics analysis of pre-treatment [
    van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
    Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
    J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic tumor burden quantified on [
    Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of the Pace of Tumor Progression as Assessed by Serial
    Camera S; Akin Telli T; Woff E; Vandeputte C; Kehagias P; Guiot T; Critchi G; Wissam Y; Bregni G; Trevisi E; Pretta A; Senti C; Leduc S; Gkolfakis P; Hoerner F; Rothé F; Sclafani F; Flamen P; Deleporte A; Hendlisz A
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y; Lu P; Yu L
    Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.
    Kwee SA; Lim J; Watanabe A; Kromer-Baker K; Coel MN
    J Nucl Med; 2014 Jun; 55(6):905-10. PubMed ID: 24676753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of volume-based parameters using
    Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
    Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
    Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
    Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.
    Frings V; van Velden FH; Velasquez LM; Hayes W; van de Ven PM; Hoekstra OS; Boellaard R
    Radiology; 2014 Nov; 273(2):539-48. PubMed ID: 24865311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY; Yen TC; Wang JY; Yang TS
    Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients.
    González de Aledo-Castillo JM; Casanueva-Eliceiry S; Soler-Perromat A; Fuster D; Pastor V; Reguart N; Viñolas N; Reyes R; Vollmer I; Paredes P; Puig-Butillé JA
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3631-3642. PubMed ID: 33797597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.